Pharmaceuticals News and Research

RSS

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

New protein 3D model could inhibit cancer development

Researchers at the University of Hertfordshire have developed a new structural model of a protein, which makes it possible to develop more effective drugs to target diseases such as cancer, heart disease and influenza.

29 Jul 2011

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

Eli Lilly introduces physician payment registry for public

Eli Lilly and Company today announced the launch of a physician payment registry to help the public better understand how the company works with U.S. physicians and compensates them for their services – and how these collaborations benefit patient care.

28 Jul 2011

Pharmaceutical companies' profit protection hurts global AIDS fight

In her latest piece on the New York Times' "Opinionator" blog, author and journalist Tina Rosenberg argues that the terms of Gilead's recent agreement with the Medicines Patent Pool is "confirmation of a dangerous new trend: middle-income countries as a target market for drug makers."

28 Jul 2011

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Ironwood Pharmaceuticals, Inc. and Depomed, Inc. today announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric retentive drug delivery technology for an Ironwood early stage development program, continuing Ironwood's efforts to augment its development pipeline beyond linaclotide.

28 Jul 2011

Smokers are misinformed about safety and efficacy of nicotine replacement therapy

Nearly half of all smokers in the United States attempt to quit at least once per year, yet the majority of these efforts fail. One factor contributing to the low annual rate of successful cessation is that the majority of quit attempts are made without evidence-based treatment such as nicotine replacement therapy.

28 Jul 2011

PCMA President releases statement on new Medicare Part D study

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement today on a new study published in the Journal of the American Medical Association that found "implementation of Medicare Part D was followed by a significant reductions in nondrug medical spending, particularly on acute and post acute care, for elderly Medicare beneficiaries with limited prior drug coverage".

28 Jul 2011

Dr. Reddy's, FUJIFILM sign MoU to enter partnership in the generic drugs business

FUJIFILM Corporation President and CEO, Shigetaka Komori and Dr. Reddy's Laboratories Ltd. Vice-Chairman and CEO, G V Prasad today signed a Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.

28 Jul 2011

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

28 Jul 2011

Watson to acquire portfolio of divested generic pharmaceutical products

Watson Pharmaceuticals, Inc. today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories.

28 Jul 2011

BioSante to offer and sell shares of common stock in an underwritten public offering

BioSante Pharmaceuticals, Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering will be sold by BioSante.

28 Jul 2011

CytRx prices underwritten public offering of common stock

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase up to 39,200,000 shares of common stock at a combined public offering price of $0.52 per share and related warrant for gross proceeds of approximately $20.4 million.

27 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Dow second quarter sales increase to $16.0 billion

Dow reported earnings of $0.84 per share. This compares with reported earnings of $0.50 per share in the same period last year.

27 Jul 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

Invaron, Columbia Laboratories enter license agreement for STRIANT buccal system

Columbia Laboratories, Inc. has entered into a license agreement with Invaron Pharmaceuticals Inc., a privately-held Canadian pharmaceutical company, for STRIANT in Canada.

27 Jul 2011

Cocaine-free topical anaesthetics can effectively treat pain caused by torn skin

While some pain killers need to be injected into the damaged tissue in order to work, topical anaesthetics only need to be spread on the surface. The earliest examples of "topical" anaesthetics contained cocaine, but now a new systematic review has shown that newer agents that don't contain cocaine can effectively treat pain caused by torn skin.

27 Jul 2011

Pharmaceuticals News and Research

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

New protein 3D model could inhibit cancer development

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

POZEN reports revenue of $4.6 million for second quarter 2011

Eli Lilly introduces physician payment registry for public

Pharmaceutical companies' profit protection hurts global AIDS fight

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Smokers are misinformed about safety and efficacy of nicotine replacement therapy

PCMA President releases statement on new Medicare Part D study

Dr. Reddy's, FUJIFILM sign MoU to enter partnership in the generic drugs business

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Watson to acquire portfolio of divested generic pharmaceutical products

BioSante to offer and sell shares of common stock in an underwritten public offering

CytRx prices underwritten public offering of common stock

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Dow second quarter sales increase to $16.0 billion

Repligen first quarter total revenue increases 9% to $7,654,000

Invaron, Columbia Laboratories enter license agreement for STRIANT buccal system

Cocaine-free topical anaesthetics can effectively treat pain caused by torn skin

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence